100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was…
Compositions and Methods for Enhancing Anti-Viral TherapiesCALGARY, Alberta, March 23, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the…
Basel, 23 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the donation of additional medicines and diagnostics…
IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different solid tumor types in an interim update…
Represents World’s First Surveillance Solutions for Investigational Use in Xenotransplantation Research and Post-Xenotransplant Clinical MonitoringSOUTH SAN FRANCISCO, Calif., March 23,…
OVAL top-line data for ofra-vec progression free survival (PFS) primary endpoint expected in 2H 2022; with positive results, VBL anticipates…
LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that…
AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics…
NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that…
NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical…